aclidinium bromide (Tudorza Pressair, Bretaris, Eklira)
Jump to navigation
Jump to search
Indications
- long-term maintenance treatment of bronchospasm associated with COPD
Contraindications
- not a rescue inhaler
Dosage
- a dry powder inhaler used twice daily
Adverse effects
- paradoxical bronchospasm
- new or worsened acute narrow-angle glaucoma
- new or worsened urinary retention
- does not worsen cardiovascular outcomes in COPD[3]
Mechanism of action
- antimuscarinic agent
- by inhibiting the muscarinic M3 receptor, it relaxes smooth muscle resulting in bronchodilation
- affinity for muscarinic receptors (M1-M5)[2]
More general terms
Component of
References
- ↑ FDA News Release: July 23, 2012 FDA approves Tudorza Pressair to treat chronic obstructive pulmonary disease http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm313052.htm
- ↑ Jump up to: 2.0 2.1 Prescriber's Letter 19(12): 2012 Tudorza Pressair (Aclidinium) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=281209&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Jump up to: 3.0 3.1 Wise RA et al. Effect of aclidinium bromide on major cardiovascular events and exacerbations in high-risk patients with chronic obstructive pulmonary disease: The ASCENT-COPD randomized clinical trial. JAMA 2019 May 7; 321:1693 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31063575 https://jamanetwork.com/journals/jama/fullarticle/2732574